Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in nonalcoholic steatohepatitis in rats

为了研究血管紧张素II受体阻滞剂是否可以预防NASH相关肝细胞癌（HCC）的发展，我们研究了ARB对胆碱-缺乏l -氨基酸（CDAA）饮食NASH模型的影响。24周CDAA饮食导致肝硬化，再24周CDAA饮食加重肝硬化，产生HCC。另一方面，新型ARB替米沙坦即使在24周CDAA日粮喂养后也能改善肝纤维化并保护肝癌发生。这些发现表明，替米沙坦对NASH诱导的HCC具有治疗潜力，即使在肝纤维化发生后也是如此。

To investigate whether angiotensin II receptor blocker could prevent the development of NASH related hepatocellular carcinoma (HCC), we examined the effect of ARB on choline-deficientL-aminoacid-defined (CDAA) diet NASH model. Twenty-four week-CDAA diet produced liver cirrhosis, and then CDAA diet for another 24 week aggravated liver cirrhosis, and produced HCC. On the other hand, telmisartan, a novel ARB, improved hepatic fibrosis and protected hepatic carcinogenesis even after 24-week CDAA diet feeding. These finding indicate that telmisartan has a therapeutic potential for NASH induced production of HCC even after hepatic fibrosis had been developed.